AAAAAA

   
Results: 1-20 |
Results: 20
Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections
Authors: Blondeau, JM
Citation: Jm. Blondeau, Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections, EXPERT OP I, 10(2), 2001, pp. 213-237
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents
Authors: Blondeau, JM Vaughan, D Laskowski, R Borsos, S
Citation: Jm. Blondeau et al., Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents, INT J ANT A, 17(6), 2001, pp. 457-464
Mutant prevention concentrations of fluoroquinolones for clinical isolatesof Streptococcus pneumoniae
Authors: Blondeau, JM Zhao, XL Hansen, G Drlica, K
Citation: Jm. Blondeau et al., Mutant prevention concentrations of fluoroquinolones for clinical isolatesof Streptococcus pneumoniae, ANTIM AG CH, 45(2), 2001, pp. 433-438
Gatifloxacin: a new fluoroquinolone
Authors: Blondeau, JM
Citation: Jm. Blondeau, Gatifloxacin: a new fluoroquinolone, EXPERT OP I, 9(8), 2000, pp. 1877-1895
A review of clinical trials with fluoroquinolones with an emphasis on new agents
Authors: Blondeau, JM
Citation: Jm. Blondeau, A review of clinical trials with fluoroquinolones with an emphasis on new agents, EXPERT OP I, 9(2), 2000, pp. 383-413
In vitro activity of 19 antimicrobial agents against 3513 nosocomial pathogens collected from 48 Canadian medical centres
Authors: Blondeau, JM Vaughan, D
Citation: Jm. Blondeau et D. Vaughan, In vitro activity of 19 antimicrobial agents against 3513 nosocomial pathogens collected from 48 Canadian medical centres, INT J ANT A, 15(3), 2000, pp. 213-219
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
Authors: Blondeau, JM Laskowski, R Bjarnason, J Stewart, C
Citation: Jm. Blondeau et al., Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms, INT J ANT A, 14(1), 2000, pp. 45-50
Untitled - Reply
Authors: Blondeau, JM
Citation: Jm. Blondeau, Untitled - Reply, J ANTIMICRO, 46(2), 2000, pp. 323-323
A review of antimicrobial resistance in Canada
Authors: Blondeau, JM Vaughan, D
Citation: Jm. Blondeau et D. Vaughan, A review of antimicrobial resistance in Canada, CAN J MICRO, 46(10), 2000, pp. 867-877
In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens
Authors: Blondeau, JM Felmingham, D
Citation: Jm. Blondeau et D. Felmingham, In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens, CLIN DRUG I, 18(1), 1999, pp. 57-78
Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infections
Authors: Blondeau, JM Tillotson, GS
Citation: Jm. Blondeau et Gs. Tillotson, Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infections, INT J ANT A, 12(2), 1999, pp. 145-150
In vitro activity of several antimicrobial agents against 1003 isolates ofStreptococcus pyogenes collected from Western Canada
Authors: Blondeau, JM Church, D Yaschuk, Y Bjarnason, J
Citation: Jm. Blondeau et al., In vitro activity of several antimicrobial agents against 1003 isolates ofStreptococcus pyogenes collected from Western Canada, INT J ANT A, 12(1), 1999, pp. 67-70
In vitro evaluation of G1: a novel antimicrobial compound
Authors: Blondeau, JM Castanedo, N Gonzalez, O Mendina, R Silveira, E
Citation: Jm. Blondeau et al., In vitro evaluation of G1: a novel antimicrobial compound, INT J ANT A, 11(2), 1999, pp. 163-166
In-vitro activity of cefepime and seven other antimicrobial agents against1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities
Authors: Blondeau, JM Laskowski, R Borsos, S
Citation: Jm. Blondeau et al., In-vitro activity of cefepime and seven other antimicrobial agents against1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities, J ANTIMICRO, 44(4), 1999, pp. 545-548
A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'
Authors: Blondeau, JM
Citation: Jm. Blondeau, A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones', J ANTIMICRO, 43, 1999, pp. 1-11
Moxifloxacin: a new respiratory quinolone - Preface
Authors: Blondeau, JM Brown, EM Wood, MJ
Citation: Jm. Blondeau et al., Moxifloxacin: a new respiratory quinolone - Preface, J ANTIMICRO, 43, 1999, pp. III-III
In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study
Authors: Blondeau, JM Yaschuk, Y Suter, M Vaughan, D
Citation: Jm. Blondeau et al., In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study, J ANTIMICRO, 43, 1999, pp. 3-23
Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis
Authors: Blondeau, JM Suter, M Borsos, S
Citation: Jm. Blondeau et al., Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis, J ANTIMICRO, 43, 1999, pp. 25-30
Expanded activity and utility of the new fluoroquinolones: A review
Authors: Blondeau, JM
Citation: Jm. Blondeau, Expanded activity and utility of the new fluoroquinolones: A review, CLIN THER, 21(1), 1999, pp. 3-40
Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin
Authors: Blondeau, JM Suter, ME Borsos, S Misfeldt, C
Citation: Jm. Blondeau et al., Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin, INT J ANT A, 10(4), 1998, pp. 297-302
Risultati: 1-20 |